SDX-308

SDX-308 (CEP-18082) is a novel indole-pyran analogue of R-etodolac (SDX-101) that lacks the cyclooxygenase (COX) inhibitory activity of its parent compound. It is being investigated for the treatment of hematologic malignancies, particularly multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), as well as solid tumors and bone-related disorders. SDX-308 exerts its anti-tumor and anti-osteoclastogenic effects by inhibiting the NF-kappaB and beta-catenin/TCF signaling pathways. This inhibition leads to the downregulation of downstream targets such as myc and survivin, induction of apoptosis via caspase activation, and complete abrogation of bone resorption. Preclinical studies have shown that SDX-308 is significantly more potent than SDX-101 and remains effective against tumor cells resistant to conventional therapies like dexamethasone and bortezomib.